Published online May 27, 2021. doi: 10.4254/wjh.v13.i5.543
Peer-review started: January 5, 2021
First decision: February 13, 2021
Revised: February 21, 2021
Accepted: March 31, 2021
Article in press: March 31, 2021
Published online: May 27, 2021
Cholestatic liver diseases are characterized by an accumulation of toxic bile acids (BA) in the liver, blood and other tissues which lead to progressive liver injury and poor prognosis in patients.
To discover and validate prognostic biomarkers of cholestatic liver diseases based on the urinary BA profile.
We analyzed urine samples by liquid chromatography-tandem mass spectrometry and investigated the use of the urinary BA profile to develop survival models that can predict the prognosis of hepatobiliary diseases. The urinary BA profile, a set of non-BA parameters, and the adverse events of liver transplant and/or death were monitored in 257 patients with cholestatic liver diseases for up to 7 years. The BA profile was characterized by calculating BA indices, which quantify the composition, metabolism, hydrophilicity, formation of secondary BA, and toxicity of the BA profile. We have developed and validated the bile-acid score (BAS) model (a survival model based on BA indices) to predict the prognosis of cholestatic liver diseases.
We have developed and validated a survival model based on BA (the BAS model) indices to predict the prognosis of cholestatic liver diseases. Our results demonstrate that the BAS model is more accurate and results in higher true-positive and true-negative prediction of death compared to both non-BAS and model for end-stage liver disease (MELD) models. Both 5- and 3-year survival probabilities markedly decreased as a function of BAS. Moreover, patients with high BAS had a 4-fold higher rate of death and lived for an average of 11 mo shorter than subjects with low BAS. The increased risk of death with high vs low BAS was also 2-4-fold higher and the shortening of lifespan was 6-7-mo lower compared to MELD or non-BAS. Similarly, we have shown the use of BAS to predict the survival of patients with and without liver transplant (LT). Therefore, BAS could be used to define the most seriously ill patients, who need earlier intervention such as LT. This will help provide guidance for timely care for liver patients.
The BAS model is more accurate than MELD and non-BAS models in predicting the prognosis of cholestatic liver diseases.
Core Tip: We have developed survival models based on bile acid (BA) indices to predict the prognosis of hepatobiliary diseases. Our BA models outperformed the model for end-stage liver disease and non-BA models in predicting the occurrence of the adverse events of death and/or liver transplant.